July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Comparison and validation of ex vivo and in vitro corneal permeability models
Author Affiliations & Notes
  • Jenni J. Hakkarainen
    R&D, Experimentica Ltd., Kuopio, Finland
  • Agne Ziniauskaite
    R&D, Experimentica Ltd., Kuopio, Finland
  • Vytautas Cepla
    Ferentis UAB, Vilnius, Lithuania
  • Ramunas Valiokas
    Ferentis UAB, Vilnius, Lithuania
  • Giedrius Kalesnykas
    R&D, Experimentica Ltd., Kuopio, Finland
  • Footnotes
    Commercial Relationships   Jenni Hakkarainen, Experimentica Ltd (F), Experimentica Ltd (I), Experimentica Ltd (E), Experimentica Ltd (P), Experimentica Ltd (R), Experimentica Ltd (S); Agne Ziniauskaite, Experimentica Ltd (F), Experimentica Ltd (E); Vytautas Cepla, Ferentis UAB (E), Ferentis UAB (P), Ferentis UAB (R); Ramunas Valiokas, Ferentis UAB (F), Ferentis UAB (I), Ferentis UAB (E), Ferentis UAB (P), Ferentis UAB (R), Ferentis UAB (S); Giedrius Kalesnykas, Experimentica Ltd (F), Experimentica Ltd (I), Experimentica Ltd (E), Experimentica Ltd (P), Experimentica Ltd (R), Experimentica Ltd (S)
  • Footnotes
    Support  Business Finland 890/31/15
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5087. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jenni J. Hakkarainen, Agne Ziniauskaite, Vytautas Cepla, Ramunas Valiokas, Giedrius Kalesnykas; Comparison and validation of ex vivo and in vitro corneal permeability models. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5087.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Early drug discovery and development require the accurate estimation of the permeability properties of topical ocular pharmaceutical formulations across the corneal barrier. The aim of this study was to compare the gold standard ex vivo rabbit corneal permeability model with our novel and validated in vitro model for corneal permeability.

Methods : The apparent permeability coefficient (Papp) was estimated for nine fluorescent reference standards (Rhodamine B, Rhodamine 123, Rhodamine 6G, Rhodamine 110 chloride, 6-carboxyfluorescein, FITC-dextrans mol. wt 4000 and 70 000, resorufin, DAPI) and six clinically used ocular drugs (brinzolamide, dexamethasone, chloramphenicol, timolol, pilocarpine and betaxolol) using a vertical diffusion chamber system. Reference standards were selected based on lipophilicity and physicochemical properties.

Results : The ophthalmic drug molecules used for this initial validation of our in vitro model exhibited a wide range of corneal permeability. Correlation analysis was performed by comparing ex vivo and in vitro Papp values with several physicochemical parameters such as molecular weight, lipophilicity, and polar surface area. Significant differences between the permeability properties of in vitro and ex vivo models were identified. Specifically, using an in vitro model with a stratified corneal epithelium overestimated the Papp values of lipophilic molecules compared with the ex vivo model (Pappvalues ranged from 0.07 to 42 × 10-6 cm/s and from impermeable to 27 × 10-6 cm/s, respectively). The prediction of Papp values was improved in an in vitro model containing a double-layered structure mimicking both the stratified epithelium and the stroma (Papp ranged from 0.2 to 34.6 × 10-6 cm/s).

Conclusions : Our data suggest that in vitro corneal permeability models require a multilayered corneal structure in order to adequately predict corneal permeability of drugs and experimental compounds.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×